Last reviewed · How we verify

NCT05032339

Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer

Completed Last updated 30 October 2023
What this trial tests

trial testing IUO Plasma Cell Disorders Panel in Plasma Cell Disorder in 208 participants. Completed in 25 October 2023.

Timeline
4 May 2021
Primary endpoint
25 October 2023
25 October 2023

Quick facts

Lead sponsorBecton, Dickinson and Company
StatusCompleted
Study typeOBSERVATIONAL
Enrollment208
Start date4 May 2021
Primary completion25 October 2023
Estimated completion25 October 2023
Sites5 locations across United Kingdom, Switzerland, Portugal, United States, Spain

Drugs / interventions tested

Conditions studied

Sponsor

Becton, Dickinson and Company — full company profile →

Who can join

22 and older, any sex, with Plasma Cell Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multi-site, prospective performance study to determine equivalency between the investigational OneFlow PCD panel on the FACSLyric system versus the final clinical diagnosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Plasma Cell Disorder

Currently open trials in the same condition.

Other Becton, Dickinson and Company trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05032339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing